Oncology Brothers: Practice-Changing Cancer Discussions

We had a chance to dive into one of the most significant advancements in the treatment of HER2-positive gastroesophageal junction (GEJ) and gastric adenocarcinoma. In this episode, we discussed the groundbreaking HERIZON-GEA-01 study that led to the approval of zanidatamab, a novel bispecific HER2-directed antibody.
 
We welcomed Dr. Nataliya Uboha, a GI medical oncologist from the University of Wisconsin, who shared her insights on the study's design, findings, and the implications for clinical practice. Learn about the importance of biomarker testing, the mechanism of action of zanidatamab, and how it compares to traditional therapies like trastuzumab.
 
Key topics covered in this episode:
Overview of the HERIZON-GEA-01 study and its findings
Mechanism of action of zanidatamab
Comparison of treatment regimens and overall survival benefits
Management of side effects, including diarrhea and infusion reactions
The role of PD-L1 testing in treatment decisions
 
Whether you're a healthcare professional or simply interested in the latest in oncology, this episode provides valuable insights into the evolving landscape of treatment for HER2-positive upper GI malignancies.
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
⁠X/Twitter: https://x.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and check out our other discussions on FDA approvals, treatment algorithms, and challenging cases!
 
#GastricCancer, #HER2positive, #Zanidatamab, #HERIZONGEA01, #OncologyBrothers
 

Welcome to the Oncology Brothers podcast and our new series, Rapid Fire Rounds! In this episode, we were joined by Dr. Joseph Mikhael, a myeloma specialist from the City of Hope, to answer 10–12 community-sourced questions on multiple myeloma management.
 
The panel covers:
Frontline therapy: Quadruplet therapy, carfilzomib vs bortezomib, and high-risk disease definitions
Maintenance strategies: Lenalidomide alone vs daratumumab-lenalidomide vs carfilzomib-lenalidomide, with insights from the ENDURANCE, ATLAS trials
Relapsed/refractory disease: Sequencing CAR T-cell therapy, bispecific antibodies (teclistamab + daratumumab), and the newly approved cereblon modulators (CELMoDs) like mezigdomide
CAR-T logistics: The critical distinction between holding therapy (pre-collection) and bridging therapy (post-collection)
Supportive care: IVIG, antiviral/antifungal prophylaxis, and monitoring for ICANS
MRD testing: Current role in clinical practice and its use as an endpoint for drug approval
 
This episode is packed with practical, actionable insights for community oncologists managing myeloma day-to-day.
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
⁠X/Twitter: https://x.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and hit the notification bell for more Rapid Fire Rounds from the Oncology Brothers!
#MultipleMyeloma, #CARTtherapy, #MRD, #CELMoD, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Sagar Lonial, a myeloma specialist from the Emory University, to discuss the recent FDA approval of iberdomide, a novel cereblon modulator (CELMoDs), in combination with daratumumab and dexamethasone for the treatment of relapsed and refractory multiple myeloma.
 
Join us as we dive into:
The significance of the EXCALIBER-RRMM study that led to the approval of iberdomide
What makes cereblon modulators different from existing immunomodulatory agents (IMiDs) and their potential benefits
The study design, findings, and the implications of minimal residual disease (MRD) as a primary endpoint for approval
Who the ideal candidates for iberdomide are and how it fits into the current treatment landscape
The side effect profile of iberdomide compared to traditional therapies and management strategies
Insights on monitoring disease status and the future of cereblon modulators in combination with other therapies
 
This episode is packed with valuable information for healthcare professionals and anyone interested in the latest advancements in multiple myeloma treatment.
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://x.com/oncbrothers 
Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
#CELMoDs, #MultipleMyeloma, #EXCALIBERstudy, #MRD, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we discussed the world of androgen receptor pathway inhibitors (ARPIs) in prostate cancer as part of our Tox Check series. Joined by esteemed guests Dr. Alicia Morgans, a GU medical oncologist from Dana-Farber Cancer Institute, and Dr. Christopher M. Pieczonka, a urologist from US Urology Partners, the discussion covered the common side effects associated with ARPIs, including cardiac issues, cognitive changes, and more.
 
Key topics included:
An overview of approved ARPIs, focusing on abiraterone, apalutamide, darolutamide, and enzalutamide
The importance of monitoring side effects and strategies to mitigate them
Insights from recent studies, highlighting the impact of these medications on patient quality of life
A discussion on the role of shared decision-making in treatment options for prostate cancer patients
 
Whether you're a healthcare professional or someone interested in prostate cancer treatment, this episode aims to equip you with valuable knowledge to better manage patient care.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:•⁠  ⁠X/Twitter: https://x.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and hit the notification bell for more insightful discussions from the Oncology Brothers!
 
#ProstateCancer, #ARPI, #SideEffectManagement, #SharedDecisionMaking, #OncologyBrothers

Join us with as we dive into two challenging cases of myelodysplastic syndromes (MDS) in this episode featuring Dr. Amer Zeidan, from the Yale School of Medicine. The discussion focused on real-life scenarios from community settings, exploring treatment decisions in both frontline settings and cases of disease progression.
In the first case, we examined a 74-year-old gentleman with persistent anemia and discussed the implications of his diagnosis, treatment options like erythropoiesis-stimulating agents (ESAs) and luspatercept, and the importance of timely intervention. The conversation highlighted the evolving landscape of MDS treatment, including the significance of molecular risk stratification and the potential for improved patient outcomes.
The second case featured a 67-year-old woman whose disease has progressed despite initial treatment with luspatercept. Dr. Zeidan shared insights on the next steps, including the use of hypomethylating agents (HMAs) , the role of transplant, and the management of side effects associated with these therapies.
Tune in for an informative discussion that not only addressed treatment strategies but also emphasized the importance of patient-centered care and the need for ongoing monitoring and support.
Don't forget to like, subscribe, and share your thoughts with us! If there are specific topics or cases you'd like us to cover in future episodes, reach out to us.
Episode Highlights:
Overview of MDS and its treatment landscape
Case discussions on treatment decisions for anemia and disease progression
Insights on the use of luspatercept and hypomethylating agents
Management of side effects and the importance of patient education
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 
Follow us on social media:•⁠  ⁠X/Twitter: https://x.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ 
Thanks for tuning in! We are the Oncology Brothers.
#MDS, #MyelodysplasticSyndrome, #HMAs, #HemeMalignancy, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Thomas LeBlanc, MD MA, from the Duke Cancer Institute to discuss the treatment algorithm for myelodysplastic syndrome (MDS).
We dived deep into the importance of risk stratification in MDS, exploring lower-risk, intermediate-risk, and higher-risk categories. Dr. LeBlanc shared insights on the role of next-generation sequencing (NGS) and the Revised International Prognostic Scoring System (IPSS-R) in guiding treatment decisions.
 
Key topics included:
Treatment options for lower-risk MDS, including the use of erythropoiesis-stimulating agents (ESAs) and luspatercept
The significance of ring sideroblasts and del(5q) in treatment selection
The management of anemia, thrombocytopenia, and neutropenia in MDS patients
The emerging role of imetelstat for heavily transfusion-dependent patients and its unique side effects
Join us as we unpacked the complexities of MDS treatment and emphasize the importance of personalized care for patients.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://x.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
Don't forget to like, subscribe, and hit the notification bell for more insightful discussions in oncology!
#MDS, #MyelodysplasticSyndrome, #RiskStratification, #OncologyBrothers

Join us in this insightful episode of our new series, Partners in Practice. We delved into the critical role of teamwork in cancer care, focusing on the treatment landscape of metastatic pancreatic cancer.
In this episode, we were joined by Dr. Timothy Brown, a GI medical oncologist from UT Southwestern, and Ms. Heather Klein, a GI-focused nurse practitioner. Together, we explored the latest treatment options, including modified FOLFIRINOX, NALIRIFOX, gemcitabine with nab-paclitaxel, and the emerging role of novel therapies like RAS inhibitors.
Key topics include:
Overview of current treatment paradigms for metastatic pancreatic cancer
Discussion of side effects and patient management strategies
The importance of communication and collaboration within the oncology team
Insights into the future of pancreatic cancer treatment and the potential of new therapies
Whether you're a healthcare professional, a patient, or simply interested in oncology, this episode offers valuable perspectives on delivering compassionate and effective cancer care.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
⁠X/Twitter: https://x.com/oncbrothers 
Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers!
#PancreaticCancer, #PartnersInPractice, #RASinhibitors, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of late relapse refractory multiple myeloma treatment. Joined by Maximilian Merz, MD, a myeloma specialist from the Memorial Sloan Kettering Cancer Center, the discussion covered the evolving treatment landscape, including the use of CAR-T cell therapies, bispecific antibodies, and the importance of assessing BCMA expression.
Key topics included:
The current treatment algorithms for late relapse refractory multiple myeloma
The significance of antigen expression in guiding treatment decisions
The role of bispecific antibodies like teclistamab and talquetamab
Managing side effects and improving patient quality of life
The importance of collaboration between community hematologists and tertiary care centers
Join us as we explored the latest advancements in myeloma treatment and the critical role of patient education and support in navigating this challenging disease. Don't forget to check out our previous episodes on newly diagnosed multiple myeloma and early relapse refractory disease!
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
⁠X/Twitter: https://x.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/ 
Subscribe for more insights and updates on oncology treatments!
#MultipleMyeloma, #CART, #BispecificAntibody, #RelapsedMyeloma, #OncologyBrothers

In this episode of the Oncology Brothers podcast we continued our treatment algorithm series, focusing on early relapsed/refractory multiple myeloma (RRMM). We were joined by Dr. Shaji Kumar, a myeloma specialist from the Mayo Clinic, who shared his insights into current evidence-based treatment strategies for patients whose disease has progressed after frontline therapy.
 
Key topics discussed included:
The current standard of care for frontline multiple myeloma, including quadruplet therapy and maintenance strategies
The role of CAR T-cell therapy and bispecific antibodies, including teclistamab and talquetamab, in early relapsed/refractory multiple myeloma
Treatment selection based on patient age, prior therapy, drug exposure, and disease biology
The importance of shared decision-making and incorporating patient preferences into treatment planning
Recent clinical trial data and emerging therapies shaping the future of multiple myeloma care
This episode provides practical insights into managing early relapsed/refractory disease and navigating today's evolving treatment landscape.
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://x.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/ 
 
Subscribe for more expert discussions on multiple myeloma, hematologic malignancies, cellular therapies, bispecific antibodies, and precision oncology.
#MultipleMyeloma #CART #BispecificAntibodies #Hematology #Oncology

Welcome to the Oncology Brothers podcast! In this episode, we dived into the latest advancements in multiple myeloma treatment, focusing on the practice changing ENDURANCE trial. Joined by esteemed guests Dr. Shaji Kumar and Dr. Vincent Rajkumar from Mayo Clinic, they discussed the new time limited approach being the standard of care for maintenance therapy in standard-risk multiple myeloma patients.
 
Key topics include:
Overview of the ENDURANCE trial and its implications for clinical practice
The significance of limiting lenalidomide maintenance therapy to two years
The role of minimal residual disease (MRD) testing in treatment decisions
Insights on high-risk cytogenetics and future directions for therapy
 
This episode is a must-listen for community oncologists and anyone interested in the evolving landscape of cancer treatment. Tune in to learn how these findings can impact patient care and improve outcomes!
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://x.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and check out our other episodes for more discussions on treatment algorithms, conference highlights, and challenging cases in oncology.
#MultipleMyeloma, #ENDURANCE, #Lenalidomide, #MRD, #OncologyBrothers